You do have a good assessment when you say that they "need capital and they need to show they can actually do this stuff and as important, that they can actually manage a public company."
Why are investors still so reluctant in investing in this company so that Arrayit gets the capital?
For OvaDx they only need $5M. investment for FDA approval. And the potential revenue is $5B.
They do say they are cash flow positive. So that's good.
Once they start getting revenues from the first blockbuster test (OvaDx) they could really develop the rest of the tests.
DaBaby and Stunna 4 Vegas's "NO DRIBBLE" Joins Music Licensing, Inc.'s Portfolio • SONGD • Jun 7, 2024 10:15 AM
Mushrooms Inc. (OTC: MSRM) Announces Significant Share Buy Back by the Board Director and New Strategic Initiatives. • MSRM • Jun 5, 2024 1:32 PM
Hydromer Announces Launch of HydroThrombX Medical Device Coating Technology • HYDI • Jun 5, 2024 10:24 AM
Dr. Michael Dent Finances $1 Million to Drive HealthLynked's Healthcare Transformation • HLYK • Jun 5, 2024 8:00 AM
Avant Technologies Enters Binding LOI to Purchase Dozens of High-Performance, Immersible, AI-Powered Servers • AVAI • Jun 5, 2024 8:00 AM
IQST - iQSTEL Announces $290 Million 2024 Annual Revenue Forecast • IQST • Jun 4, 2024 1:43 PM